Back to results
US 2022/0016162 A1Published application
Compositions and methods for treating bone injury
AssigneeBoard of Regents, The University of Texas System
InventorVaida Glatt
Life of this patent
Estimating the term…
Abstract
The disclosure relates to compositions and methods of treating, improving, and accelerating the healing of large segmental bone defects in a subject. The method comprises administering to a patient in need of treatment an effective amount of whole blood, sodium citrate, ecarin and BMP-2.
Claims32
An ex vivo hematoma comprising:
- (a) isolated whole blood;
- (b) sodium citrate;
- and (c) ecarin;
- oscutarin and calcium chloride;
- calcium chloride;
- thrombin;
- or thrombin and calcium chloride;
- wherein the ex vivo hematoma comprises fibrin fibers having a thickness of at least 150-300 nm±10%.
5 more elements
An ex vivo hematoma comprising:
- (a) platelet rich plasma, plasma, or plasma with red blood cells;
- and (b) ecarin;
- oscutarin and calcium chloride;
- calcium chloride;
- thrombin;
- or thrombin and calcium chloride;
- wherein the ex vivo hematoma comprises fibrin fibers having a thickness of at least 150-300 nm±10%.
4 more elements
(canceled)
9-16. (canceled)
(canceled)
21-25. (Canceled)
(canceled)
(canceled)
31-38. (canceled)
41-43. (canceled)
A method of constructing an implant, the method comprising:
- a) dimensioning a depot implant in at least one of a shape and a size that facilitates implantation of the depot implant into a bone defect;
- and
- b) structuring the depot implant to have a scaffold by introducing (i) isolated whole blood and sodium citrate;
- or platelet rich plasma, plasma, or plasma with red blood cells;
- and (ii) ecarin;
- oscutarin and calcium chloride;
- calcium chloride;
- thrombin;
- or thrombin and calcium chloride to create the scaffold;
- wherein the scaffold has a porosity of 55 to 75%.
7 more elements
(canceled)
(canceled)
(canceled)
52-54. (canceled)
Dependencies are inferred from the claim text.